Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Antibiotic ‘Superteam’ Could Quash Invincible Superbug

By Ryan Bushey | August 22, 2017

A novel combination of aztreonam, amikacin and polymyxin B was able to kill E. coli carrying mcr-1 and ndm-5 — genes that make the bacterium immune to last-resort antibiotics. Source: University of Buffalo

A trio of antibiotics could hold the key to eradicating a deadly superbug for good.

Researchers at the University of Buffalo discovered a novel combination of aztreonam, amikacin, and polymyxin B – a last resort antibiotic — was able to simultaneously kill E. coli bacterium strains carrying mcr-1 and ndm-5 genes within 24 hours while also preventing regrowth.

E.coli carrying the mcr-1 and ndm-5 genes have made it immune to last-resort antibiotics.

Polymyxins are considered as a  treatment option when all else has failed because, while effective, they can cause kidney damage.  Scientists explored new dosing strategies and therapeutic combinations in an effort to avoid prescribing high doses of these drugs and make up for the medication’s weaknesses.

The team performed studies on dozens of combinations of more than 15 antibiotics paired with polymyxin B.

Two combinations with either aztreonam or amikacin emerged as the best candidates producing undetectable bacterial counts after a 24-hour period.

However, the bacteria was able to regrow to initial levels after 96 hours whereas strains resistant to amikacin formed after 10 days. The fusion of polymixin B and aztreonam made the E.coli enter into a persistent but non-replicating state.

Overall, combining all three treatments together yielded the best results.

“We knew that polymyxins alone couldn’t work. Only the three drugs combined were able to work synergistically to suppress and kill the bacteria,” said Zackery Bulman, PharmD, the first author of the study and a graduate of the University of Buffalo’s School of Pharmacy and Pharmaceutical Sciences. “We overcame the bacteria by pushing it as far as possible with an agent that it was resistant to while simultaneously administering two other antibiotics.”

There have been less than two dozen cases reported of infections with this pathogen in the United States, but additional cases reported worldwide have shown how the bacteria’s immunity to available treatments leaves the medical community vulnerable to a massive outbreak of infections.

“We believe that the appearance of mcr-1 and ndm-5 in patients may be a harbinger for what is to come. The golden era of antibiotics isn’t over yet, but we wanted to help clinicians prepare therapeutically for the occurrence of these strains,” continued Bulman.

Findings from this experiment were published in the journal, mBio.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE